Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Background: Previous studies have suggested that varenicline, an α4β2 nicotinic receptor partial agonist, and α7 nicotinic receptor full agonist, may be effective for the treatment of methamphetamine (MA) dependence due to dopaminergic effects, relief of glutamatergic and cognitive dysfunction, and activation of nicotinic cholinergic systems. This study aimed to determine if varenicline (1 mg BID) resulted in reduced methamphetamine use compared to placebo among treatment-seeking MA-dependent volunteers. Methods: Treatment-seeking MA-dependent volunteers were randomized to varenicline 1 mg twice daily (n = 27) or placebo (n = 25) and cognitive behavioral therapy for 9 weeks. The primary outcomes were the proportion of participants achieving end-of-treatment-abstinence (EOTA, MA-negative urine specimens during weeks 8 and 9) and the treatment effectiveness score (TES, number of MA-negative urine specimens) for varenicline versus placebo. Results: There was no significant difference in EOTA between varenicline (15%, 4/27) and placebo (20%, 5/25; p = 0.9). There was some suggestion that urinary confirmed medication compliance corresponded with EOTA in the varenicline condition, though it did not reach statistical significance, OR = 1.57 for a 100 ng/ml increase in urine varenicline, p = 0.10, 95% CI (0.99, 3.02). There was no significant difference in mean TES in the varenicline condition (8.6) compared to the placebo condition (8.1), and treatment condition was not a statistically significant predictor of TES, IRR = 1.01, p = 0.9, 95% CI (0.39, 2.70). Conclusions: The results of this study indicate that 1 mg varenicline BID was not an effective treatment for MA dependence among treatment-seeking MA-dependent volunteers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Using Bayes to get the most out of non-significant results
Dienes, Z. (2014) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.00781 · Cited by 1,998 · cited 2×
“Addiction researchers have promoted the use of Bayes factors to enhance the interpretation of trial results, both positive and negative (Dienes, 2014; West, 2016).”
BackgroundMethodGonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 1×
“Varenicline is an α4β2 nicotinic receptor partial agonist and α7 nicotinic receptor full agonist that is approved for cigarette smoking cessation (Gonzales et al., 2006) and shows promise for treating alcohol dependence (de Bejczy et al., 2015; Litten et al., 2013; McKee et al., 2009).”
BackgroundEnsuring balanced distribution of prognostic factors in treatment outcome research.
Stout, R. L., Wirtz, P. W., Carbonari, J. P., & Del Boca, F. K. (1994) · Journal of Studies on Alcohol, Supplement · doi:10.15288/jsas.1994.s12.70 · Cited by 461
Nicotine receptor partial agonists for smoking cessation
Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006103.pub7 · Cited by 433 · cited 1×
“This small trial in a highly-selected group of MA users cannot rule out rare cardiac or psychiatric adverse events although recent meta-analyses support the safety of varenicline in general populations including those with psychiatric illness (Cahill et al., 2016; Chelladurai and Singh, 2014; Thomas et al., 2018).”
ResultLitten, R. Z., Ryan, M. L., Fertig, J. B., Falk, D. E., Johnson, B., Dunn, K. E., Green, A. I., Pettinati, H. M., Ciraulo, D. A., Sarid-Segal, O., et al. (2013) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e31829623f4 · Cited by 287 · cited 1×
“, 2006) and shows promise for treating alcohol dependence (de Bejczy et al., 2015; Litten et al., 2013; McKee et al., 2009).”
BackgroundBupropion for the treatment of methamphetamine dependence
Elkashef, A. M., Rawson, R. A., Anderson, A. L., Li, S.-H., Holmes, T., Smith, E. V., Chiang, N., Kahn, R., Vocci, F., Ling, W., et al. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301481 · Cited by 234 · cited 1×
“, 2013), instead only efficacious in subpopulations defined by baseline MA use (Elkashef et al., 2008; Ling et al., 2014; Shoptaw et al., 2008) or among men who have sex with men (Colfax et al.”
BackgroundMirtazapine to Reduce Methamphetamine Use: A Randomized Controlled Trial
Colfax, G. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.124 · Cited by 175 · cited 1×
“, 2008) or among men who have sex with men (Colfax et al., 2011).”
BackgroundThe Economic Cost of Methamphetamine Use in the United States, 2005
Nicosia, N., Pacula, R., Kilmer, B., Lundberg, R., & Chiesa, J. (2009) · doi:10.7249/mg829 · Cited by 136 · cited 1×
“Approximately 469,000 people aged 12 and older in the U.S. meet the DSM-IV criteria for MA dependence, and the economic burden of MA use in the U.S. is approximately $23.4 billion per year (Nicosia et al., 2009; Substance Abuse and Mental Health Services Administration, 2014).”
BackgroundInfluentialAnderson, A. L., Li, S.-H., Markova, D., Holmes, T. H., Chiang, N., Kahn, R., Campbell, J., Dickerson, D. L., Galloway, G. P., Haning, W., et al. (2015) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2015.01.036 · Cited by 70 · cited 1×
“Potential pharmacotherapies have been investigated in randomized, placebo-controlled trials for MA dependence, but results have failed to identify a medication with a robust effect in generalized populations of MA users (Anderson et al., 2015; Courtney and Ray, 2014; Heinzerling et al., 2014; Miles et al., 2013; Pérez…”
BackgroundHeinzerling, K. G., Swanson, A., Hall, T. M., Yi, Y., Wu, Y., & Shoptaw, S. J. (2014) · Addiction · doi:10.1111/add.12636 · Cited by 64 · cited 1×
“…have failed to identify a medication with a robust effect in generalized populations of MA users (Anderson et al., 2015; Courtney and Ray, 2014; Heinzerling et al., 2014; Miles et al., 2013; Pérez-Mañá et al., 2013), instead only efficacious in subpopulations defined by baseline MA use…”
BackgroundSelf-citation
Cited by
Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review
Siefried, K. J., Acheson, L. S., Lintzeris, N., & Ezard, N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00711-x · Cited by 194
Pharmacotherapy for methamphetamine/amphetamine use disorder—a systematic review and meta‐analysis
Chan, B., Freeman, M., Kondo, K., Ayers, C., Montgomery, J., Paynter, R., & Kansagara, D. (2019) · Addiction · doi:10.1111/add.14755 · Cited by 160
Turner, D., Briken, P., Grubbs, J., Malandain, L., Mestre-Bach, G., Potenza, M. N., & Thibaut, F. (2022) · Dialogues in Clinical Neuroscience · doi:10.1080/19585969.2022.2134739 · Cited by 86
Hersi, M., Corace, K., Hamel, C., Esmaeilisaraji, L., Rice, D., Dryburgh, N., Skidmore, B., Garber, G., Porath, A., Willows, M., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0292745 · Cited by 13
“Naltrexone; Placebo [55] 3.”
BackgroundInfluential
Metadata
- Authors
- Briones, M., Shoptaw, S., Cook, R., Worley, M., Swanson, A.-N., Moody, D. E., Fang, W. B., Tsuang, J., Furst, B., & Heinzerling, K.
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2018-08
- Volume
- 189
- Pages
- 30-36
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2804645708
- Cited by
- 17
- References
- 11
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial. https://app.cochat.ai/papers/10.1016/j.drugalcdep.2018.04.023
- The paper
- Briones, M., Shoptaw, S., Cook, R., Worley, M., Swanson, A.-N., Moody, D. E., Fang, W. B., Tsuang, J., Furst, B., & Heinzerling, K. (2018). Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial. Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2018.04.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.